RecruitingNot ApplicableNCT05844865
Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis
Sponsor
University of California, Irvine
Enrollment
20 participants
Start Date
May 4, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This is a pilot study gathering and using samples and data from patients with gastrointestinal peritoneal carcinomatosis. Participants will be asked for permission to provide blood and ascites/peritoneal wash fluid, tumor samples during their planned surgical procedure.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Patients must have a GI tumor
- Must have planned standard of care surgical procedure
- Age ≥ 18 years.
- Ability to understand and the willingness to sign a written informed consent
Exclusion Criteria1
- \- Pattens who are unable to comply with the study protocol
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERBiospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)
Subjects with a known diagnosis of GI primary tumor with or without PC, with a planned standard of care surgery.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05844865
Related Trials
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
NCT048470631 location
Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
NCT074938762 locations
Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
NCT047795542 locations
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
NCT0700174810 locations
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
NCT0650414710 locations